engleski

A case-control study of genotoxicity endpoints in patients with papillary thyroid cancer

According to the World Health Organization, one third of all cancers are preventable. Cancer prevention could be improved through the biomonitoring of genome integrity using cytogenetic tools: cytokinesis-block micronucleus (CBMN) assay and comet assay. During recent years, thyroid cancer has been one of the fastest growing cancer types in the world, but data regarding genome damage in thyroid cancer patients are lacking. We therefore performed a case-control study on 23 untreated papillary thyroid cancer (PTC) patients using CBMN and comet assay. When compared to 23 healthy volunteers matched for gender, age, and smoking status, PTC patients showed higher basal DNA damage in peripheral blood lymphocytes. The CBMN assay indicated that the number of micronuclei, nuclear buds, and nucleoplasmic bridges among the cases were respectively 2.67-, 2.79-, and 7.72-fold higher than among the controls (p<0.05). The results of comet assay showed that the tail length and tail intensity among the cases were respectively 1.20- and 1.94-fold higher than among the controls (p<0.05). Additionally, 14 thyroid tissues from the PTC patients were immunohistochemically Raf-B and Ret labelled and all were positive for at least one protein. Although the human biomonitoring and risk assessments could be valuable approaches in cancer prediction, the need to find a greater number of specific biomarkers evaluated in larger study groups, as well as to develop programs for individuals identified as high- risk groups of population, still exists.

Micronucleus test ; Comet assay ; Papillary thyroid cancer ; Cancer prevention ; Raf-B ; Ret

nije evidentirano